Modification of COPD Presentation During the Last 25 Years

REFERENCES

• Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest 2003 May; 123(5):1684–1692.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004 Aug 14; 364(9434):613–620.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006 Jan; 27(1):188–207.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997 May 3; 349(9061):1269–1276.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007 Sep 1; 370(9589):797–799.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002 Oct; 57(10):847–852.
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977 Jun 25; 1(6077):1645–1648.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 Feb 22; 356(8):775–789.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 Oct 9; 359(15):1543– 1554.
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins C, Jones PW, Effect of Pharmacotherapy on Rate of Decline of Lung Function in COPD: Results from the TORCH Study. Am J Respir Crit Care Med 2008; 178:332–338.
   Web of Science ®Google Scholar
• van Gestel YR, Hoeks SE, Sin DD, Simsek C, Welten GM, Schouten O, Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008 Jul 15;102(2):192–196.
   PubMed Web of Science ®Google Scholar
• Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009 Jun 3;10:45.
   PubMed Web of Science ®Google Scholar
• Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010 May 24; 170(10):880–887.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001 Apr; 163(5):1256–1276.
   PubMedGoogle Scholar
• Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003 Aug; 124(2):459–467.
   PubMed Web of Science ®Google Scholar
• Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined co-morbidity index. J Clin Epidemiol 1994 Nov; 47(11):1245–1251.
   PubMed Web of Science ®Google Scholar
• Crisafulli E, Costi S, Luppi F, Cirelli G, Cilione C, Coletti O, Role of co-morbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. Thorax 2008 Jun; 63(6):487–492.
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993 Mar; 16:5–40.
   PubMedGoogle Scholar
• Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med 2007 Mar 1; 175(5):458–463.
   PubMed Web of Science ®Google Scholar
• Janssens W, Lehouck A, Carremans C, Bouillon R, Mathieu C, Decramer M. Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act. Am J Respir Crit Care Med 2009 Apr 15; 179(8):630–636.
   PubMed Web of Science ®Google Scholar
• Franssen FM, O’Donnell DE, Goossens GH, Blaak EE, Schols AM. Obesity and the lung: 5. Obesity and COPD. Thorax 2008 Dec; 63(12):1110–1117.
   PubMed Web of Science ®Google Scholar
• Zanobetti A, Bind MA, Schwartz J. Particulate air pollution and survival in a COPD cohort. Environ Health 2008 Oct 10; 7:48.
   PubMed Web of Science ®Google Scholar
• Brown DW, Croft JB, Greenlund KJ, Giles WH. Average age at death from COPD in the United States: 1980–85, 1990–95, 2000–05. COPD 2009 Jun; 6(3):152–154.
   PubMedGoogle Scholar
• Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009 Nov 15; 180(10):948–955.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002 Aug 1; 166(3):333–339.
   PubMed Web of Science ®Google Scholar
• Braman SS, Lee DW. Primary care management of chronic obstructive pulmonary disease: an integrated goal-directed approach. Curr Opin Pulm Med 2010 Mar; 16(2):83–88.
   PubMed Web of Science ®Google Scholar
• Gross N, Levin D. Primary care of the patient with chronic obstructive pulmonary disease-part 2: pharmacologic treatment across all stages of disease. Am J Med 2008 Jul; 121(7 Suppl):S13–S24.
   Google Scholar
• Vlahakos DV, Kosmas EN, Dimopoulou I, Ikonomou E, Jullien G, Vassilakos P, Association between activation of the renin-angiotensin system and secondary erythrocytosis in patients with chronic obstructive pulmonary disease. Am J Med 1999 Feb; 106(2):158–164.
   PubMed Web of Science ®Google Scholar
• Andreas S, Herrmann-Lingen C, Raupach T, Luthje L, Fabricius JA, Hruska N, Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J 2006 May; 27(5):972–979.
   PubMed Web of Science ®Google Scholar